Diabetes medicine may improve autoimmune disorder outcomes

A study published in Cell Metabolism has suggested that the commonly used medicine for type 2 diabetes, canagliflozin, may be repurposed to treat T-cell driven autoimmunity as the medicine reduces T-cell activation. The scientists hope to move the study to clinical trials.

News Medical